Mba Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 03-12-2024
- Paid Up Capital ₹ 2.00 M
as on 03-12-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 Cr
as on 03-12-2024
- Satisfied Charges ₹ 1.00 Cr
as on 03-12-2024
- Revenue 3.75%
(FY 2022)
- Profit 883.04%
(FY 2022)
- Ebitda 65.34%
(FY 2022)
- Net Worth 9.31%
(FY 2022)
- Total Assets 18.06%
(FY 2022)
About Mba Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹1.20 Cr. The company has closed loans amounting to ₹1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jitender Kumar and Girish Kalra serve as directors at the Company.
- CIN/LLPIN
U51397DL2014PTC265441
- Company No.
265441
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Mba Pharmaceuticals Private Limited offer?
Mba Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Common Disease Medicines, Injectable Products, Immunization & Vaccination Drugs, Vaccines, Anti Infective Drugs & Medicines, Anti Infective Agent.
Who are the key members and board of directors at Mba Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitender Kumar  | Director | 26-Feb-2014 | Current |
| Girish Kalra | Director | 26-Feb-2014 | Current |
Financial Performance of Mba Pharmaceuticals.
Mba Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.75% increase. The company also saw a substantial improvement in profitability, with a 883.04% increase in profit. The company's net worth moved up by a moderate rise of 9.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mba Pharmaceuticals?
In 2022, Mba Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Aug 2019 | ₹1.20 Cr | Open |
Ing Vysya Bank Limited Creation Date: 26 Nov 2014 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Mba Pharmaceuticals?
Unlock and access historical data on people associated with Mba Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mba Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mba Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
